Emma Ogburn

2.6k total citations · 1 hit paper
19 papers, 382 citations indexed

About

Emma Ogburn is a scholar working on Oncology, Economics and Econometrics and Cancer Research. According to data from OpenAlex, Emma Ogburn has authored 19 papers receiving a total of 382 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Oncology, 5 papers in Economics and Econometrics and 5 papers in Cancer Research. Recurrent topics in Emma Ogburn's work include Breast Cancer Treatment Studies (5 papers), HER2/EGFR in Cancer Research (5 papers) and Sleep and related disorders (4 papers). Emma Ogburn is often cited by papers focused on Breast Cancer Treatment Studies (5 papers), HER2/EGFR in Cancer Research (5 papers) and Sleep and related disorders (4 papers). Emma Ogburn collaborates with scholars based in United Kingdom, Qatar and Ireland. Emma Ogburn's co-authors include Richard Hobbs, Ly‐Mee Yu, Victoria Harris, Michelle A. Detry, Mark Fitzgerald, Oliver van Hecke, Philip Evans, Mihir Patel, Jienchi Dorward and Nicholas Thomas and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and PLoS ONE.

In The Last Decade

Emma Ogburn

17 papers receiving 375 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Azithromycin for community treatment of suspected COVID-19 in people at increased risk of an adverse clinical course in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial

2021 180 citations Christopher Butler, Jienchi Dorward et al. The Lancet profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Emma Ogburn United Kingdom	10	107	66	60	52	51	19	382
Saurabh Aggarwal United States	9	269 2.5×	65 1.0×	7 0.1×	12 0.2×	82 1.6×	17	563
Elena Olariu Spain	9	30 0.3×	254 3.8×	5 0.1×	31 0.6×	27 0.5×	22	532
Adrian Root United Kingdom	9	37 0.3×	85 1.3×	9 0.1×	15 0.3×	20 0.4×	14	380
Sara Mucherino Italy	10	91 0.9×	44 0.7×	11 0.2×	4 0.1×	28 0.5×	27	335
Natalie Flaks‐Manov Israel	11	103 1.0×	74 1.1×	12 0.2×	4 0.1×	13 0.3×	30	530
Chulaporn Limwattananon Thailand	13	26 0.2×	91 1.4×	9 0.1×	47 0.9×	16 0.3×	40	555
Thomas G. Cantú United States	6	160 1.5×	64 1.0×	8 0.1×	38 0.7×	20 0.4×	10	476
Stuart McTaggart United Kingdom	9	21 0.2×	72 1.1×	19 0.3×	3 0.1×	16 0.3×	21	294
Young Choi South Korea	12	49 0.5×	52 0.8×	2 0.0×	21 0.4×	12 0.2×	29	348
Aurelio Sessa Italy	16	57 0.5×	171 2.6×	67 1.1×	3 0.1×	14 0.3×	32	665

Countries citing papers authored by Emma Ogburn

Since Specialization

Citations

This map shows the geographic impact of Emma Ogburn's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Emma Ogburn with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Emma Ogburn more than expected).

Fields of papers citing papers by Emma Ogburn

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Emma Ogburn. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Emma Ogburn. The network helps show where Emma Ogburn may publish in the future.

Co-authorship network of co-authors of Emma Ogburn

This figure shows the co-authorship network connecting the top 25 collaborators of Emma Ogburn. A scholar is included among the top collaborators of Emma Ogburn based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Emma Ogburn. Emma Ogburn is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

Kyle, Simon D., Peter Bower, Ly‐Mee Yu, et al.. (2024). Nurse-delivered sleep restriction therapy to improve insomnia disorder in primary care: the HABIT RCT. Health Technology Assessment. 28(36). 1–107. 2 indexed citations

Smith, Matthew E., Oliver Rivero‐Arias, Kim Rand, et al.. (2024). Digital thErapy For Improved tiNnitus carE Study (DEFINE): Protocol for a randomised controlled trial. PLoS ONE. 19(1). e0292562–e0292562.

Hobbs, Richard J., Oghenekome Gbinigie, Emma Ogburn, et al.. (2023). Inhaled Budesonide for COVID-19 in People at Higher Risk of Complications in the Community: The UK National Community Randomi. PubMed. 3859–3859. 1 indexed citations

Siriwardena, A Niroshan, Simon D. Kyle, Peter Bower, et al.. (2023). Nurse-delivered sleep restriction therapy in primary care for adults with insomnia disorder: a mixed-methods process evaluation. British Journal of General Practice. 74(738). e34–e40. 3 indexed citations

Kyle, Simon D., A Niroshan Siriwardena, Colin A. Espie, et al.. (2023). Clinical and cost-effectiveness of nurse-delivered sleep restriction therapy for insomnia in primary care (HABIT): a pragmatic, superiority, open-label, randomised controlled trial. The Lancet. 402(10406). 975–987. 38 indexed citations

Hirst, Jennifer, José M Ordóñez-Mena, Christopher A. O’Callaghan, et al.. (2021). Prevalence and factors associated with multimorbidity among primary care patients with decreased renal function. PLoS ONE. 16(1). e0245131–e0245131. 14 indexed citations

Butler, Christopher, Jienchi Dorward, Ly‐Mee Yu, et al.. (2021). Azithromycin for community treatment of suspected COVID-19 in people at increased risk of an adverse clinical course in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial. The Lancet. 397(10279). 1063–1074. 180 indexed citations breakdown →

Kyle, Simon D., Claire Madigan, Lucy Abel, et al.. (2020). Primary care treatment of insomnia: study protocol for a pragmatic, multicentre, randomised controlled trial comparing nurse-delivered sleep restriction therapy to sleep hygiene (the HABIT trial). BMJ Open. 10(3). e036248–e036248. 10 indexed citations

Hirst, Jennifer, Nathan R. Hill, Christopher A. O’Callaghan, et al.. (2020). Prevalence of chronic kidney disease in the community using data from OxRen: a UK population-based cohort study. British Journal of General Practice. 70(693). e285–e293. 49 indexed citations

10.

Crowley, Evelyn M., Shaun Treweek, Katie Banister, et al.. (2020). Using systematic data categorisation to quantify the types of data collected in clinical trials: the DataCat project. Trials. 21(1). 535–535. 10 indexed citations

11.

Sheppard, James P, Jenni Burt, Mark Lown, et al.. (2018). OPtimising Treatment for MIld Systolic hypertension in the Elderly (OPTiMISE): protocol for a randomised controlled non-inferiority trial. BMJ Open. 8(9). e022930–e022930. 10 indexed citations

12.

Hirst, Jennifer, Clare Taylor, José M Ordóñez-Mena, et al.. (2018). Impact of a single eGFR and eGFR-estimating equation on chronic kidney disease reclassification: a cohort study in primary care. British Journal of General Practice. 68(673). e524–e530. 17 indexed citations

13.

Franssen, Marloes, Andrew Farmer, Sabrina Grant, et al.. (2017). Telemonitoring and/or self-monitoring of blood pressure in hypertension (TASMINH4): protocol for a randomised controlled trial. BMC Cardiovascular Disorders. 17(1). 58–58. 15 indexed citations

14.

Earl, Helena, Anne-Laure Vallier, Janet Dunn, et al.. (2016). Trastuzumab-associated cardiac events in the Persephone trial. British Journal of Cancer. 115(12). 1462–1470. 22 indexed citations

15.

Earl, Helena, David Cameron, David Miles, et al.. (2014). PERSEPHONE: Duration of trastuzumab with chemotherapy in patients with HER2-positive early breast cancer—Six versus twelve months.. Journal of Clinical Oncology. 32(15_suppl). TPS656–TPS656. 3 indexed citations

16.

Earl, Helena, David Cameron, David Miles, et al.. (2014). PERSEPHONE is a randomised phase III controlled trial comparing six months of trastuzumab to the standard 12 months in patients with HER2 positive early breast cancer. European Journal of Surgical Oncology. 40(5). 619–619. 1 indexed citations

17.

Earl, Helena, David Cameron, David Miles, et al.. (2013). PERSEPHONE: Duration of trastuzumab with chemotherapy in women with HER2-positive early breast cancer—Six versus twelve months.. Journal of Clinical Oncology. 31(15_suppl). TPS667–TPS667. 1 indexed citations

18.

Earl, Helena, David Cameron, David Miles, et al.. (2012). The PERSEPHONE trial: Duration of trastuzumab with chemotherapy in women with HER2-positive early breast cancer.. Journal of Clinical Oncology. 30(15_suppl). TPS660–TPS660. 5 indexed citations

19.

Hiller, Louise, Janet Dunn, Helen Higgins, et al.. (2011). Optimising patient recall of adverse events over prolonged time periods. Trials. 12(S1). 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact